India Pharma Outlook Team | Wednesday, 21 October 2026
Innovation accelerates as Western drugmakers race to secure next-generation platforms.
Roche locks in a massive antibody-drug conjugate partnership with China’s Hansoh Pharma valued at over USD 15 billion.
AstraZeneca teams up with Oracle to accelerate AI-driven clinical trials, while Eli Lilly partners with Hong Kong-listed Metis TechBio on advanced drug delivery technology worth up to USD 1.1 billion.
These deals highlight strong Western demand for Chinese oncology expertise, AI tools, and tissue-targeted delivery systems.
Leading companies act fast to secure advanced platforms that transform research pipelines and deliver stronger results for patients in key therapeutic areas.
China’s Hansoh Pharmaceutical enters a partnership and licensing deal with Roche’s unit F. Hoffmann-La Roche that potentially exceeds USD 15 billion. The agreement covers a portfolio of antibody-drug conjugate programs. Hansoh receives an upfront payment of USD 400 million, a first-anniversary payment of USD 110 million, and additional milestone payments.
Hansoh leads early development of the programs until the companies complete global Phase Ia clinical trials. Roche then develops the programs worldwide, except in mainland China, Hong Kong, Macau, and Taiwan, where Hansoh retains rights to develop, register, and commercialize them.
Hansoh also holds the option to co-develop up to two programs outside those markets. The companies previously partnered on colorectal cancer treatments, building on an existing relationship that now expands into broader oncology innovation.
Also Read: Building Scalable MedTech Ecosystem for India's Healthcare Future
AstraZeneca works with Oracle to deploy AI and real-world data that identify eligible patients for clinical trials and monitor safety signals. The collaboration combines AstraZeneca’s drug-development expertise with Oracle’s AI and healthcare data capabilities to support patient matching and research.
Initial efforts focus on cancer, cardiovascular, respiratory, immunology, and rare diseases. The work could also enable earlier diagnosis of serious conditions. The first project supports hypertension research in Abu Dhabi in partnership with UAE-based healthcare firm M42.
Patient recruitment ranks among the biggest challenges in clinical research because delayed enrolment often extends trial timelines and raises development costs. AstraZeneca seeks to expand its medicine portfolio as it targets over USD 80 billion in annual revenue by 2030 and addresses industry bottlenecks in drug development.
Hong Kong-listed Metis TechBio enters a collaboration agreement with Eli Lilly worth up to USD 1.1 billion to research and develop tissue-specific drug-delivery technologies. The Chinese biotech applies its proprietary AI-driven drug delivery platform to create next-generation solutions that improve how lipid-nanoparticle-based drugs reach target tissues.
Metis becomes eligible for an upfront payment in the low double-digit millions of U.S. dollars and up to about USD 1.1 billion in development, regulatory, and commercial milestone payments. The company also earns tiered royalties at a single-digit percentage of annual net sales of products that emerge from the collaboration.
Metis and Lilly aim to discover and optimize novel lipid-nanoparticle architectures that enhance tissue specificity and therapeutic performance, with potential applications across multiple disease areas. The platform centers on AI-driven ionizable lipid discovery and optimization.
These multi-billion-dollar moves underscore how pharma giants actively pursue Chinese innovation in antibody-drug conjugates, AI for clinical research, and advanced delivery systems to stay ahead in the next wave of medicine.
.jpg)
